Tag: Sigilon Therapeutics
Lilly wraps up Sigilon Therapeutics acquisition to amplify Type 1 diabetes research
Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer, Sigilon Therapeutics, Inc. (NASDAQ: SGTX). This strategic ... Read More
Eli Lilly Q2 2023 financial results highlight robust 28% revenue growth
Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven by volume growth from Mounjaro, Verzenio, Jardiance, ... Read More
Lilly to transform chronic disease management with Sigilon Therapeutics acquisition
Pharmaceutical giant Eli Lilly and Company (Lilly) has announced its definitive agreement to acquire Nasdaq-listed biopharma innovator Sigilon Therapeutics, in a move set to significantly ... Read More